Acronym | MURYXIN |
|---|---|
Call | ERA-NET JPIAMR-ACTION
|
Implementation period | 26.06.2023. – 25.06.2026. |
Project Coordinator | Francesc Rabanal, University of Barcelona, Spain |
Partners | Matilda Bäckberg, RISE Research Institutes of Sweden, Sweden
|
Pawel Baranczewski, Uppsala University, Sweden | |
Timothy R Walsh, University of Oxford, United Kingdom | |
Edgars Liepinsh, Latvian Institute of Organic Synthesis, Latvia | |
Carina Vingsbo-Lundberg, Statens Serum Institute, Denmark | |
Klaus Skovbo Jensen, CANDOR Simulation, Denmark | |
Total costs | € 1 510 899 |
Costs for Latvian partner | € 300 000 |
About MURYXIN project
The project presents an innovative chemical tool to be applied to known cyclic peptide antibiotics.
The rationale of the design consists of maintaining the overall structure of the antibiotic to preserve the antibacterial activity while the presence of the chemical tool within the peptide backbone would facilitate the initial metabolization and detoxification by oxidorreductases upon eventual accumulation of the antibiotic in the kidney.
The project follows a proof-of-concept scheme involving the necessary chemistry to prepare the model compounds, the in vitro and in vivo assays to assess activity and low toxicity, and estimate a therapeutic window. Finallly, tests to prove the design hypothesis and the mechanism of action at the membrane level are also proposed.